ArticleTherapeutics and clinical risk management2010
Molecular mechanisms and treatment strategies for Dupuytren's disease.
Article in Therapeutics and clinical risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Development of a 3D In Vitro Model of Dupuytren's Disease as a Platform for Drug Screening.Cellular and molecular bioengineering · 2026Article
- THE UNITÉ RHUMATOLOGIQUE DES AFFECTIONS DE LA MAIN (URAM): TRANSLATION INTO PORTUGUESE, CULTURAL ADAPTATION AND VALIDATION.Acta ortopedica brasileira · 2026Article
- Alterations in the Structure, Composition, and Organization of Galactosaminoglycan-Containing Proteoglycans and Collagen Correspond to the Progressive Stages of Dupuytren's Disease.International journal of molecular sciences · 2024Article
- Nanostring-Based Identification of the Gene Expression Profile in Trigger Finger Samples.Healthcare (Basel, Switzerland) · 2021Article
- The Effect of Chitosan Derivatives on the Compaction and Tension Generation of the Fibroblast-populated Collagen Matrix.Molecules (Basel, Switzerland) · 2019Article
- Multiple Recurrences in Aggressive Forms of Dupuytren's Disease-Can Patients Benefit from Repeated Selective Fasciectomy?Plastic and reconstructive surgery. Global open · 2017Article
- Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren's contracture.Hand (New York, N.Y.) · 2013Article
- Operative trends and physician treatment costs associated with Dupuytren's disease in Canada.The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique · 2013Article
- Multiple concurrent collagenase clostridium histolyticum injections to Dupuytren's cords: an exploratory study.BMC musculoskeletal disorders · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dupuytren's disease (DD) is a common disease of the hand and is characterized by thickening of the palmar fascia and formation of tight collagenous disease cords. At present, the disease is incurable and the molecular pathophysiology of DD is unknown. Surgery remains the most commonly used treatment for DD, but this requires extensive postoperative therapy and is associated with high rates of recurrence. Over the past decades, more indepth exploration of the molecular basis of DD has raised the hopes of developing new treatment modalities. This paper reviews the clinical presentation and molecular pathophysiology of this disease, as well as current and emerging treatment. It also explores the implications of new findings in the laboratory for future treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.